Your browser is no longer supported. Please, upgrade your browser.
ACET Adicet Bio, Inc. daily Stock Chart
Adicet Bio, Inc.
Index- P/E- EPS (ttm)-13.79 Insider Own- Shs Outstand19.59M Perf Week-21.59%
Market Cap197.24M Forward P/E- EPS next Y-2.38 Insider Trans- Shs Float5.37M Perf Month-26.34%
Income-66.00M PEG- EPS next Q-0.77 Inst Own12.40% Short Float- Perf Quarter-29.11%
Sales4.39M P/S44.96 EPS this Y-69.50% Inst Trans28.70% Short Ratio- Perf Half Y38.53%
Book/sh13.59 P/B0.78 EPS next Y39.30% ROA-71.60% Target Price- Perf Year-82.64%
Cash/sh3.80 P/C2.78 EPS next 5Y29.10% ROE-78.10% 52W Range6.02 - 69.16 Perf YTD1.34%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-84.69% Beta-
Dividend %- Quick Ratio20.70 Sales past 5Y- Gross Margin- 52W Low75.91% ATR2.02
Employees18 Current Ratio20.70 Sales Q/Q125.90% Oper. Margin- RSI (14)39.41 Volatility17.94% 13.85%
OptionableYes Debt/Eq0.00 EPS Q/Q70.10% Profit Margin- Rel Volume0.12 Prev Close10.57
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume161.09K Price10.59
Recom2.50 SMA20-25.80% SMA50-32.69% SMA200-13.66% Volume978 Change0.19%
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors or T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. Its products pipeline includes ADI-001, which is in Phase 1 clinical study to treat non-Hodgkin's lymphoma; and ADI-002 that is in Phase 1 clinical study for the treatment of hepatocellular carcinoma and other solid tumors. The company is based in Menlo Park, California.